Prediction of residual disease after chemotherapy in advanced NSGCT –⁠ does microRNA provide clinical benefits?

Czech version

Authors: MUDr. Tomáš Pokrivčák, Ph.D. ¹; doc. Mgr. Roman Hrstka, Ph.D. ²; Mgr. Jan Švancara ³; doc. MUDr. Radek Lakomý, Ph.D. ¹; prof. MUDr. Alexandr Poprach, Ph.D. ¹; doc. MUDr. Michal Staník, Ph.D. ⁴; MUDr. Iva Babánková ⁵; MUDr. Jan Křístek, Ph.D. ⁶; prof. MUDr. Igor Kiss, Ph.D., MBA ¹
Authors‘ workplace: Klinika komplexní onkologické péče LF MU a MOÚ, Brno ¹; Výzkumné centrum aplikované molekulární onkologie, MOÚ, Brno ²; Institut biostatistiky a analýz, LF MU, Brno ³; Oddělení urologické onkologie, Klinika operační onkologie LF MU a MOÚ, Brno ⁴; Oddělení onkologické patologie, MOÚ, Brno ⁵; Oddělení radiologie, MOÚ, Brno ⁶
Published in: Klin Onkol 2026; 39(5): 337-343
Category: Original Articles
doi: https://doi.org/10.48095/ccko2026337

Overview

Background: Surgical resection of residual retroperitoneal masses (RPLND) is the standard of care for advanced non-seminomatous germ cell tumors of the testis (NSGCT) following curative chemotherapy. However, only necrosis or fibrosis is present in the resectate in approximately 40–50% of patients. Serum microRNAs represent promising biomarkers of germ cell tumors that could contribute to the identification of a residual viable tumor after systemic treatment. The aim of this study was to evaluate the diagnostic yield of selected microRNAs in predicting the histopathological findings in patients indicated for RPLND after chemotherapy. Patients and methods: A cohort of 18 patients with clinical stage II and III NSGCT was analyzed at the Masaryk Memorial Cancer Institute between 2021 and 2023 after completing curative chemotherapy. In all patients, levels of five specific serum microRNAs (miR-371a-3p, miR-223-3p, miR-383-3p, miR-517a-3p, and miR-519a-3p) were analyzed before beginning chemotherapy, and subsequently before and after the planned surgical procedure (RPLND). Results were correlated with the definitive histopathological findings in the resectate to assess the diagnostic yield and predictive value of these biomarkers for the presence of a viable tumor, teratoma, or necrosis. Results: Eighteen patients with advanced NSGCT were included in the analysis. The most frequent baseline clinical stages were stage IIB (33%; N = 6) and IIC (22%; N = 4). Histopathological examination of the residual tissue after PC-RPLND demonstrated necrosis in 55% (N = 10), teratoma in 38% (N = 7), and a viable tumor in 5% (N = 1). Serum tumor markers (alpha-fetoprotein –⁠ AFP, human chorionic gonadotropin –⁠ hCG, and lactate dehydrogenase –⁠ LDH) showed the expected decrease following the initiation of systemic therapy, which persisted after RPLND. The median AFP level decreased from 17.4 before therapy to 3.7 before RPLND and further to 2.5 after RPLND. A similar trend was observed for hCG and LDH. Receiver operating characteristic analysis of miRNAs as potential predictors of a teratoma or viable tumor after RPLND did not demonstrate sufficient discriminatory ability for any of the evaluated variables. Area under the curve values for most miRNAs ranged between 0.45 and 0.70, and none of the tested models reached statistical significance. Conclusion: Currently, serum microRNA levels do not reach sufficient sensitivity or specificity for decision-making regarding the indication of surgical resection of residual masses after chemotherapy in NSGCT patients. Although these biomarkers exhibit high diagnostic potential in other stages of the disease, their use in post-chemotherapy remains limited, and surgical resection of residual masses continues to represent a standard component of the curative approach.

Keywords:

biomarkers – microRNA – NSGCT – testicular germ cell tumors – miR-371a-3p – retroperitoneal lymph node dissection – RPLND

Sources

1. Gillessen S, Sauvé N, Collette L et al. The International Germ Cell Cancer Collaborative Group (IGCCCG) update: a model for predicting outcomes for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol 2021; 39 (14): 1563–1574. doi: 10.1200/JCO.20.03296.

2. Oldenburg J, Berney DM, Bokemeyer C et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33 (4): 362–375. doi: 10.1016/j.annonc.2022.01.002.

3. Patrikidou A, Cazzaniga W, Oing C et al. European Association of Urology guidelines on testicular cancer: summary of the 2026 guidelines. Eur Urol 2026; 90 (2): 163–174. doi: 10.1016/j.eururo.2026.03.021.

4. National Comprehensive Cancer Network. Testicular Cancer (Version 1.2026). [online]. Available from: https: //www.nccn.org/professionals/physician_gls/pdf/testicu-lar.pdf. [cit. 16. 3. 2026].

5. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53 (3): 478–496. doi: 10.1016/j.eururo.2007.12.024.

6. Conduit C, Hong W, Martin F et al. A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours. Front Oncol 2022; 12 : 931509. doi: 10.3389/fonc.2022.931509.

7. Oechsle K, Hartmann M, Brenner W et al. [18F]Fluorodeoxyglucose positron emission tomography in non--seminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 2008; 26 (36): 5930–5935. doi: 10.1200/JCO.2008.17.1157.

8. Nappi L, Thi M, Lum A et al. Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol 2019; 37 (33): 3090–3098. doi: 10.1200/JCO. 18.02057.

9. Badia RR, Abe D, Wong D et al. Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor management. J Urol 2021; 205 (1): 137–144. doi: 10.1097/JU.0000000000001337.

10. Dieckmann KP, Grobelny F, Soave A et al. Serum levels of MicroRNA-371a-3p for predicting the histology of postchemotherapy residual masses of germ cell tumours. Eur Urol Focus 2024; 10 (5): 851–857. doi: 10.1016/j.euf.2024.05.002.

11. Thor A, Myklebust MP, Grenabo Bergdahl A et al. miR-371a-3p predicting viable tumor in patients undergoing retroperitoneal lymph node dissection for metastatic testicular cancer: the SWENOTECA-MIR Study. J Urol 2024; 212 (5): 720–730. doi: 10.1097/JU.0000000000004164.

12. Kardoust Parizi M, Singla N, Daneshmand S et al. Diagnostic efficacy of serum microRNAs in predicting pathology of retroperitoneal lymph node dissection in patients with testicular germ cell tumors: a systematic review and meta-analysis. World J Urol 2025; 43 (1): 192. doi: 10.1007/s00345-025-05571-y.

13. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143 (1): 29–36. doi: 10.1148/radiology.143.1.7063747.

14. Honecker F, Aparicio J, Berney D et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (8): 1658–1686. doi: 10.1093/annonc/mdy217.

15. Nason GJ, Jewett MAS, Bostrom PJ et al. Long-term surveillance of patients with complete response following chemotherapy for metastatic nonseminomatous germ cell tumor. Eur Urol Oncol 2021; 4 (2): 289–296. doi: 10.1016/j.euo.2020.08.007.

16. Antonelli L, Ardizzone D, Ravi P et al. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer 2023; 182 : 144–154. doi: 10.1016/j.ejca.2022.12.032.

17. Ozgun G, Abdalvand N, Ozcan G et al. Machine learning model integrating computed tomography image--derived radiomics and circulating miRNAs to predict residual teratoma in metastatic nonseminoma testicular cancer. JCO Clin Cancer Inform 2025; 9: e2500105. doi: 10.1200/CCI-25-00105.

18. Mego M, van Agthoven T, Gronesova P et al. Clinical utility of plasma miR-371a-3p in germ cell tumors. J Cell Mol Med 2019; 23 (2): 1128–1136. doi: 10.1111/jcmm.14013.

19. Chavarriaga J, Langleben C, Lobo J et al. MicroRNA as a liquid biomarker to detect malignancy in small testicular masses. Eur Urol Oncol 2025; 8 (6): 1575–1582. doi: 10.1016/j.euo.2025.08.004.

20. Fankhauser CD, Christiansen AJ, Rothermundt C et al. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer 2022; 126 (8): 1140–1144. doi: 10.1038/s41416-021-01643-z.

21. Belge G, Dumlupinar C, Nestler T et al. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study. Clin Cancer Res 2024; 30 (2): 404–412. doi: 10.1158/1078-0432.CCR-23-0730.